New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export ABBV’s income statement to Excel — free account
AbbVie Inc.
ABBVHealthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.
- Revenue
- +10.3%
- EPS
- +2,270.0%
- Free cash flow
- +9.97%
- Total debt
- +17.7%
Quarter to September 2026, against a year earlier
288.61
5.10
+1.80%
Follow ABBV
Alert me
Ratios over time Q4 FY25 to Q3 FY26
Returns on capital
ROIC was 20.2% in Q3 FY26, the highest of these four quarters.
ROEROIC
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| ROE | 6155.9% | −139.6% | −208.1% | −288.7% |
| ROIC | 16.0% | 16.8% | 18.1% | 20.2% |
Debt
Net debt is 8.63× a year’s EBITDA.
Net debt / EBITDA
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Net debt / EBITDA | 9.5× | 10.7× | 7.7× | 8.6× |
Cash cycle, in days
Customers pay in 75 days, inventory is held 112 days and suppliers are paid in 724. Suppliers fund 538 days of working capital.
Days to pay suppliersDays to be paid
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Cash cycle | −522 | −497 | −482 | −538 |
| Days to pay suppliers | 696 | 669 | 662 | 724 |
| Days to be paid | 75 | 73 | 78 | 75 |
Per share, from Q4 FY25
Since Q4 FY25, per share: free cash flow has grown 5.93%; revenue has grown 7.94%.
Free cash flowRevenue
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Free cash flow | 1.0× | 1.1× | 1.0× | 1.1× |
| Revenue | 1.0× | 1.0× | 1.1× | 1.1× |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
7 | 7 | 5 | 8 |
+8 more TTM periods Free account |
| (288.69%) | (208.10%) | (139.61%) | 6,155.88% | ||
| 7.32% | 4.61% | 2.64% | 3.11% | ||
ROIC |
20.23% | 18.07% | 16.85% | 15.96% | |
Return on Tangible Assets |
3,229.47% | (288.01%) | (124.65%) | (48.68%) | |
Average Days of Receivables |
74.69 | 78.37 | 72.51 | 75.13 | |
Free Cash Flow per Share |
10.67 | 10.29 | 11.29 | 10.07 | |
Free Cash Flow |
18,872.00 | 18,210.00 | 19,980.00 | 17,816.00 | |
Capital Expenditures |
(1,217.00) | (1,297.00) | (1,244.00) | (1,214.00) | |
| Other line items | |||||
Cash ROIC |
21.66% | 25.47% | 26.42% | 25.64% | |
Accounts Receivable Turnover |
5.02 | 4.87 | 5.03 | 5.20 | |
Accounts Payable Turnover |
0.51 | 0.56 | 0.57 | 0.55 | |
Inventory Turnover |
3.39 | 3.64 | 3.85 | 3.99 | |
Average Days of Payables |
724.47 | 661.85 | 669.25 | 696.44 | |
Days of Inventory on Hand |
111.63 | 101.90 | 100.05 | 99.27 | |
Tax Rate |
(0.19) | (0.27) | (0.39) | (0.36) | |
Research and Development Expense of Revenue |
15.09% | 15.09% | 15.12% | 14.87% | |
Selling, General and Administrative Expense of Revenue |
23.01% | 22.79% | 22.76% | 22.91% | |
Share Based Compensation of Revenue |
1.40% | 1.52% | 1.57% | 1.56% | |
Interest Coverage |
7.93 | 6.38 | 5.80 | 5.74 | |
Operating CF/Net income |
1.95 | 3.11 | 5.90 | 4.55 | |
Depreciation/Fixed assets |
1.29 | 1.50 | 1.56 | 1.60 | |
Capex/Depreciation |
(0.16) | (0.15) | (0.14) | (0.14) | |
Revenue per Share |
37.32 | 36.40 | 35.49 | 34.57 | |
Operating CF per Share |
11.36 | 11.03 | 11.99 | 10.76 | |
Capex per Share |
(0.69) | (0.73) | (0.70) | (0.69) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 |
Columns are period end dates · fundamentals updated Nov 18, 2026